Therefore, our results suggest that PIEZO1 primarily contributes to worse survival outcomes in HR-negative patients and specifically in TNBC, implying that PIEZO1 may have different effects in different subtypes of breast cancer. The gene discussed is PIEZO1; the disease is breast cancer.